Alzheimer's Disease Trial, By Invitation NCT07595666 Sponsor: prof. dr. Koen Van Laere Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, By Invitation

NCT07595666
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been referred by their doctor for a standard PET scan as part of their usual medical care, for one of the conditions covered by this trial.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are not willing to avoid unusual, unaccustomed, or strenuous physical activity starting 4 days before the scan tracer injection and until 1 day after the injection.
  • People who do not understand what the study involves.
  • People who are unwilling or unable to complete all study procedures, or who the lead doctor considers unsuitable for any reason.
  • People who have been exposed to ionizing radiation (more than 1 mSv) as part of another research study within the past 12 months.
  • People who do not agree to have any unexpected findings shared with their general practitioner and with themselves.
  • People who are not able to give their own consent (this applies particularly to certain sub-studies involving neurodegeneration conditions).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Sponsor
prof. dr. Koen Van Laere
Registry
ClinicalTrials.gov
Start date
30 September 2025
Est. completion
31 August 2030

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Difference in diagnostic accuracy and/or diagnostic confidence of ultra-high resolution PET/CT compared to standard PET/CT and validated against clinical follow-up, or pathological/surgical outcomes in neurodegenerative disorders.; Difference in diagnostic accuracy and/or diagnostic confidence of ultra-high resolution PET/CT compared to standard PET/CT and validated against clinical follow-up, or pathological/surgical outcomes in head and neck cancer.; Comparison of the sensitivity, specificity and accuracy of ultra-high resolution PET vs. standard-of-care PET for the diagnosis of vasculitis a...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov